Introduction {#sec0005}
============

Brucellosis is the most frequently encountered world-wide zoonotic disease endemic at the Mediterranean, Middle Eastern, South Asia and South America regions. The disease is caused by a gram-negative, non-encapsulated, non-motile facultative intracellular coccobacilli of the genus *Brucella* \[[@bib0005]\]. Brucellosis is transmitted to humans by direct contact with infected animals through cuts, abrasions or aerosols. Additonally, transmission can occur by ingestion of unpasteurized milk and milk products from infected animals. Animals that are most commonly infected and can transmit the disease to humans include sheep, goat, cattle, swine \[[@bib0010]\]. Human brucellosis is a multisystemic disease that often presents with broad spectrum of clinical manifestations including fever and malaise, and complicated by focal involvement such as neurobrucellosis, endocarditis, and arthritis \[[@bib0015],[@bib0020]\].

Endocarditis caused by infection of an automated implantable cardioverter- defibrillator (AICD) or pacer is a rare complication of brucellosis, which often leads to the removal of the device \[[@bib0020], [@bib0025], [@bib0030]\]. Diagnosis of pacemaker endocarditis is based on clinical findings, echocardiography, blood culture and serology. Neurobrucellosis is a complication of systemic brucellosis infection characterized by neurological complications including encephalitis, meningoencephalitis, subarachnoid hemorrhage, myelitis, radiculitis, psychiatric manifestations, peripheral and cranial neuropathies, and myelitis \[[@bib0035]\]. We report a case pacer infection by *Brucella melitensis* in a patient with previous history of neurobrucellosis. Additionally, we summarize previous reported cases of *Brucella*-mediated endocarditis.

Case report {#sec0010}
===========

A 41-year-old male presented to the pacemaker clinic with bulging of the left breast region at the pocket site of a pacer that was placed 8 years earlier due to sick sinus syndrome. The patient, who worked in slaughterhouse, denied fever, sweating, joint or muscle pain. The surgical scar appeared healed but the region was swollen, soft, non-tender and without regional lymph node enlargement. The patient's general non-infectious disease history was remarkable for diabetes mellitus managed by diet only and for untreated gout.

Diagnostic needle puncture of the pacemaker pocket revealed purulent fluid positive for *B. melitensis.* Blood cultures were negative but serology titer for *Brucella* by Rose Bengal test was 1/2560. A transesophageal echocardiography (TEE) revealed two vegetations on the lead (8.0 x 3.0 mm and 6.0 x 3.0 mm) ([Fig. 1](#fig0005){ref-type="fig"}). The results showed no evidence of vegetation at the cardiac valves. In light of these findings the patient was diagnosed with *Brucella*-induced pacemaker lead endocarditis and a three-drug regimen, gentamicin (240 mg/day), doxycycline (200 mg/day) and rifampin (600 mg/day) was initiated. Following recommendations the pacer was removed. The postoperative course was uneventful and the patient remained completely asymptomatic 3 months later with 1/40 serological titer. Three years after pacer removal, we performed our last follow-up, which was unremarkable, and device reimplantation was not considered.Fig. 1Vegetations on pacemaker lead. Transthoracic echocardiography, parasternal long axis view showing a large vegetation in the pacemaker lead in a case of *brucella* infective endocarditis (A). 3D transesophageal echocardiography showing a pedunculated echodense mass in a portion of the lead (B). RA, right atrium. RV, right ventricle.Fig. 1

Interestingly, two years prior presentation the patient was hospitalized for severe headache lasting 3 weeks. Neurobrucellosis was diagnosed by CSF analysis which revealed WBC 190 cells/mm^3^, 76% PMN, protein 180 mg/dL, glucose 22 mg/dL and serology titer for *Brucella* of 1/160 by Rose Bengal. Blood cultures were negative. TEE, abdominal ultrasound and nuclear bone scan were unremarkable. The patient was started with a three-drug regimen with rifampin (600 mg/day) and ceftriaxone (4.0 g/day) for 4 weeks and doxycycline (200 mg/day) for 8 weeks. After 4 weeks, blood, CSF culture and serology were negative and within normal parameters. During hospitalization, pacer removal was considered, but given the absence of clinical evidence of pacemaker infection, sterile blood cultures, and the rapid clinical response to antimicrobial treatment, pacemaker was not eventually removed.

Discussion {#sec0015}
==========

Infection of the pocket and/or the leads of a pacemaker or AICD are complications representing 10% of all cases of endocarditis \[[@bib0040]\]. Although rare, *Brucella* endocarditis is a life threatening complication of brucellosis \[[@bib0040],[@bib0045]\]. The prevailing management is device removal and extended combination therapy with doxycycline and rifampin for 8--12 weeks, together with an aminoglycoside for the first 4 weeks of the treatment \[[@bib0050]\]. There are no specific guidelines regarding timing of new device reimplantation.

In the current case, neurobrucellosis was diagnosed two years prior to the pacemaker infection in a patient who was not bacteremic shown to be with no evidence of vegetations on TEE. The patient was optimally treated and remained asymptomatic until a relapse of *Brucella* infection was observed after 24 months. The patient did not report unpasteruzed milk consumption so the likelihood of the *Brucella* infection in this case was occupational. We hypothesized that disease relapse was due to biofilm formation either at the pocket with organisms traveling along the track to the lead tip, or at the lead \[[@bib0055],[@bib0060]\]. Additionally, the intracellular location of the bacterium with occult bacteremia, too low to be detected in blood cultures, may also have played a role in hindering eradication. The recommendation for device extraction for infection include evidence of valvular or lead endocarditis, pocket infection, or occult staphylococcal bacteremia or persistent occult gram negative bacteremia despite appropriate antimicrobial therapy \[[@bib0030]\]. In our case, the patient did not meet the criteria for device extraction when first diagnosed with neurobrucellosis.

A literature review on endocarditis mediated by infection of the pacer provides some insights ([Table 1](#tbl0005){ref-type="table"}). Interestingly, pacer infection leading to endocarditis can present at any time after pacer implantation. Upon infection patients required device removal. Additionally, we noted that half of the patients with pacer-endocarditis presented sick sinus syndrome as primary condition. Our current case raises the issue of timing of removal of the cardiac device, suggesting an early rather than late removal in the face of any brucellosis infection regardless of the presence or absence of bacteremia. Our case also suggests that routine serological follow-up is required in cases of systemic *Brucella* infection to not overlook the rare complication of infective endocarditis. Lastly, an unresolvable issue is the timing for insertion of a new pacer in a patient with unusual organisms. According to recent guidelines \[[@bib0030]\], the new implantation can be done after 72 h of repeated negative blood cultures on appropriate antimicrobial (recommendation Class IIa, level of evidence C). This refers to extracellular organisms, e.g., staphylococci. Additionally, this report highlights the need to review and update the current guidelines \[[@bib0030]\] for the care of patients with suspected or established pacer infections and include intracellular organisms such as *Brucella*.Table 1Clinical characteristics of patients with ICD infection due to *Brucella melitensis*.Table 1YearAgeSexLocationDevice placement\
to symptoms (years)Reason for ICDSymptomsDevice removedCo-morbiditiesAntibiotics receivedPatient A \[[@bib0065]\]201870MKuwaiti1SSSFeverNo^&^T2DM, HTN, A.FibRifampicin, doxycyclinePatient B^§^2018^§^41MIsrael8SSSSwollen in the pacemaker regionYesN/AGentamicin, doxycycline, rifampinPatient C \[[@bib0070]\]201261MGreece2N/APapular lesions at pacemaker implantation siteYesN/ADoxycycline, rifampicinPatient D \[[@bib0075]\]200870MGreece7SSSFever, back pain\
and night sweats,N/AGrave's disease, dilated cardiomyopathyDoxycycline Ciprofloxacin, RifampicinPatient E \[[@bib0025]\]200666MUS3Non-ischemic cardiomyopathyMild malaise, local pain, redness, swelling at ICD site^\*^YesT2DM, COPD, dyslipidemiasDoxycycline, ciprofloxacinPatient F \[[@bib0025]\]200770FItaly3N/AMalaise; pain, swellingyesN/ARifampin, minocycline, ciprofloxacin[^1]
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[^1]: SSS, sick sinus syndrome. T2DM, type 2 diabetes mellitus. HTN, hypertension. COPD, chronic obstructive pulmonary disease. §- Present case. \*Authors did not reported vegetations. & Elderly patients with multiple comorbidities. Patient under continous follow-up. Year, year of publication. Number, corresponding reference.
